Cambridge Investment Research Advisors
GALT icon

Cambridge Investment Research Advisors’s Galectin Therapeutics GALT Stock Holding History

Cambridge Investment Research Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$606K Buy
130,648
+2,000
+2% +$5.18K ﹤0.01% 2782
2026
Q1 		$359K Buy
128,648
+2,629
+2% +$8K ﹤0.01% 3116
2025
Q4 		$524K Buy
126,019
+4,815
+4% +$25.4K ﹤0.01% 2672
2025
Q3 		$513K Sell
121,204
-111
-0.1% -$418 ﹤0.01% 2657
2025
Q2 		$256K Buy
121,315
+2,730
+2% +$4.08K ﹤0.01% 3113
2025
Q1 		$145K Hold
118,585
– – ﹤0.01% 3280
2024
Q4 		$153K Buy
118,585
+3,865
+3% +$9.26K ﹤0.01% 3248
2024
Q3 		$315K Buy
114,720
+2,590
+2% +$6.36K ﹤0.01% 2796
2024
Q2 		$253K Sell
112,130
-9,011
-7% -$27.4K ﹤0.01% 2839
2024
Q1 		$290K Sell
121,141
-5,440
-4% -$10.3K ﹤0.01% 2725
2023
Q4 		$210K Sell
126,581
-11,591
-8% -$22.5K ﹤0.01% 2860
2023
Q3 		$265K Buy
138,172
+3,840
+3% +$6.32K ﹤0.01% 2587
2023
Q2 		$193K Sell
134,332
-8,071
-6% -$13.7K ﹤0.01% 2891
2023
Q1 		$299K Sell
142,403
-9,168
-6% -$14.8K ﹤0.01% 2494
2022
Q4 		$171K Buy
151,571
+910
+0.6% +$1.21K ﹤0.01% 2799
2022
Q3 		$246K Buy
150,661
+1,922
+1% +$3.59K ﹤0.01% 2532
2022
Q2 		$195K Buy
148,739
+3,532
+2% +$5.08K ﹤0.01% 2725
2022
Q1 		$234K Sell
145,207
-7,820
-5% -$15.1K ﹤0.01% 2753
2021
Q4 		$317K Sell
153,027
-11,471
-7% -$32.8K ﹤0.01% 2483
2021
Q3 		$638K Sell
164,498
-3,818
-2% -$12.9K ﹤0.01% 1858
2021
Q2 		$539K Buy
+168,316
New +$599K ﹤0.01% 1989
2021
Q1 		– Sell
-179,556
Closed -$402K – 2916
2020
Q4 		$402K Sell
179,556
-11,639
-6% -$30.5K ﹤0.01% 1920
2020
Q3 		$510K Sell
191,195
-11,732
-6% -$32.9K ﹤0.01% 1588
2020
Q2 		$621K Sell
202,927
-1,897
-0.9% -$4.77K ﹤0.01% 1428
2020
Q1 		$401K Buy
204,824
+14,144
+7% +$34.4K ﹤0.01% 1507
2019
Q4 		$545K Sell
190,680
-42,964
-18% -$149K ﹤0.01% 1528
2019
Q3 		$857K Buy
233,644
+1,090
+0.5% +$3.94K 0.01% 1159
2019
Q2 		$965K Buy
232,554
+56,332
+32% +$244K 0.01% 1038
2019
Q1 		$900K Buy
+176,222
New +$846K 0.01% 1095

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Cambridge Investment Research Advisors's GALT Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Galectin Therapeutics (GALT) stake by 1.6% in Q2 2026, buying an estimated $5.18K and bringing the position to 130,648 shares worth $606K. The position accounts for ﹤0.01% of the portfolio, ranked #2782.

Cambridge Investment Research Advisors first reported a position in GALT in Q1 2019 and has held it in 29 quarters since. The position peaked at $965K in Q2 2019. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Cambridge Investment Research Advisors held 130,648 shares of Galectin Therapeutics worth $606K as of Q2 2026.
  • Cambridge Investment Research Advisors bought 2,000 Galectin Therapeutics shares in Q2 2026, an estimated $5.18K.
  • Galectin Therapeutics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2782 holding.
  • Cambridge Investment Research Advisors first reported a position in Galectin Therapeutics in Q1 2019 and has held it in 29 quarters since.
  • Cambridge Investment Research Advisors's Galectin Therapeutics position peaked at $965K in Q2 2019.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.